RT Journal Article
SR Electronic
T1 Persistent oxidative stress and inflammasome activation in CD14<sup>high</sup>CD16<sup>-</sup> monocytes from COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.13.21263292
DO 10.1101/2021.09.13.21263292
A1 Lage, Silvia Lucena
A1 Amaral, Eduardo Pinheiro
A1 Hilligan, Kerry L.
A1 Laidlaw, Elizabeth
A1 Rupert, Adam
A1 Namasivayan, Sivaranjani
A1 Rocco, Joseph
A1 Galindo, Frances
A1 Kellogg, Anela
A1 Kumar, Princy
A1 Poon, Rita
A1 Wortmann, Glenn W.
A1 Shannon, John P.
A1 Hickman, Heather D.
A1 Lisco, Andrea
A1 Manion, Maura
A1 Sher, Alan
A1 Sereti, Irini
YR 2021
UL http://medrxiv.org/content/early/2021/09/16/2021.09.13.21263292.abstract
AB The poor outcome of the coronavirus disease-2019 (COVID-19), caused by SARS-CoV-2, is associated with systemic hyperinflammatory response and immunopathology. Although inflammasome and oxidative stress have independently been implicated in COVID-19, it is poorly understood whether these two pathways cooperatively contribute to disease severity. Herein, we found an enrichment of CD14highCD16- monocytes displaying inflammasome activation evidenced by caspase-1/ASC-speck formation in severe COVID-19 patients when compared to mild ones and healthy controls, respectively. Those cells also showed aberrant levels of mitochondrial superoxide (MitoSOX) and lipid peroxidation, both hallmarks of the oxidative stress response, which strongly correlated with caspase-1 activity. In addition, we found that NLRP3 inflammasome-derived IL-1β secretion by SARS-CoV-2- exposed monocytes in vitro was partially dependent on lipid peroxidation. Importantly, altered inflammasome and stress responses persisted after short- term patient recovery. Collectively, our findings suggest oxidative stress/NLRP3 signaling pathway as a potential target for host-directed therapy to mitigate early COVID-19 hyperinflammation as well as its long-term outcomes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis project was supported in part by the intramural research program of NIAID/NIH, with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. KH was supported by a Malahan Institute Postdoctoral Fellowship. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The authors declare no competing financial interests.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study participants were enrolled in the NIH clinical protocol: COVID-19-associated Lymphopenia Pathogenesis Study in Blood (CALYPSO), NCT04401436, which recruited at the NIH clinical center, Washington Hospital Center and Georgetown University Hospital. Healthy volunteer blood samples were obtained under the protocol 99-CC-0168 and were de-identified prior to distribution. Protocols in this study were reviewed and approved by the National Institutes of Health (NIH) Central Intramural Institutional Review Board (IRB). All participants provided written informed consent prior to any study procedures in accordance with the Declaration of Helsinki.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI state that all data are available in the manuscript files.